Literature DB >> 9502629

Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study.

B Cantin1, F Gagnon, S Moorjani, J P Després, B Lamarche, P J Lupien, G R Dagenais.   

Abstract

OBJECTIVES: This study was undertaken to determine whether lipoprotein(a) [Lp(a)] is an independent risk factor for ischemic heart disease (IHD) and to establish the relation of Lp(a) to the other lipid fractions.
BACKGROUND: Several, but not all, studies have shown that elevated Lp(a) concentrations may be associated with IHD; very few have been prospective.
METHODS: A 5-year prospective follow-up study was conducted in 2,156 French Canadian men 47 to 76 years old, without clinical evidence of IHD. Lipid measurements obtained at baseline included total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, apoprotein B and Lp(a). During the follow-up period, there were 116 first IHD events (myocardial infarction, angina, death). Adjusted proportional hazards models were used to estimate the relative risk for the different variables. The cohort was also classified according to Lp(a) levels and other lipid risk factor tertiles to evaluate the relation of elevated Lp(a) levels to these risk factors. A cutoff value of 30 mg/dl was used for Lp(a). Risk ratios were calculated using the group with low Lp(a) levels and the first tertile of lipid measures as a reference.
RESULTS: Lp(a) was not an independent risk factor for IHD but seemed to increase the deleterious effects of mildly elevated LDL cholesterol and elevated total cholesterol and apoprotein B levels and seemed to counteract the beneficial effects associated with elevated HDL cholesterol levels.
CONCLUSIONS: In this cohort, Lp(a) was not an independent risk factor for IHD but appeared to increase the risk associated with other lipid risk factors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9502629     DOI: 10.1016/s0735-1097(97)00528-7

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  30 in total

1.  Clinical implications of elevated lipoprotein(a).

Authors:  A von Eckardstein; G Assmann
Journal:  Curr Atheroscler Rep       Date:  2001-07       Impact factor: 5.113

Review 2.  Lipoprotein(a) and coronary heart disease risk.

Authors:  S M Marcovina; R A Hegele; M L Koschinsky
Journal:  Curr Cardiol Rep       Date:  1999-07       Impact factor: 2.931

3.  Common problems in the management of hypertriglyceridemia.

Authors:  Michelle A Fung; Jiri J Frohlich
Journal:  CMAJ       Date:  2002-11-26       Impact factor: 8.262

Review 4.  Lipoprotein(a): an elusive cardiovascular risk factor.

Authors:  Lars Berglund; Rajasekhar Ramakrishnan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-09-02       Impact factor: 8.311

Review 5.  Screening for and management of elevated Lp(a).

Authors:  Michael B Boffa; Marlys L Koschinsky
Journal:  Curr Cardiol Rep       Date:  2013-11       Impact factor: 2.931

Review 6.  Cardiovascular risk assessment: a global perspective.

Authors:  Dong Zhao; Jing Liu; Wuxiang Xie; Yue Qi
Journal:  Nat Rev Cardiol       Date:  2015-03-10       Impact factor: 32.419

Review 7.  Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.

Authors:  Børge G Nordestgaard; Anne Langsted
Journal:  J Lipid Res       Date:  2016-09-27       Impact factor: 5.922

Review 8.  The role of non-LDL:non-HDL particles in atherosclerosis.

Authors:  Jere P Segrest
Journal:  Curr Diab Rep       Date:  2002-06       Impact factor: 4.810

9.  Hyperlipoproteinaemia(a) is a common cause of autosomal dominant hypercholesterolaemia.

Authors:  E Meriño-Ibarra; J Puzo; E Jarauta; A Cenarro; D Recalde; A L García-Otín; E Ros; E Martorell; X Pintó; M Franco; D Zambón; A Brea; M Pocoví; F Civeira
Journal:  J Inherit Metab Dis       Date:  2007-10-20       Impact factor: 4.982

Review 10.  Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.

Authors:  Sebhat Erqou; Stephen Kaptoge; Philip L Perry; Emanuele Di Angelantonio; Alexander Thompson; Ian R White; Santica M Marcovina; Rory Collins; Simon G Thompson; John Danesh
Journal:  JAMA       Date:  2009-07-22       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.